Almonty's Legal Exposure and a Korean Listing Ambition Put Its Revaluation-Heavy Profit Under the Microscope
Published on 11/18/2026 at 21:21 | Editorial boerse-global.deAlmonty's third-quarter headline profit of C$50.2 million is more than its entire quarterly revenue — a quirk of accounting that tells investors almost nothing about whether the tungsten miner can actually make money. What matters far more is a smaller figure buried in the same November 12 release: adjusted EBITDA of C$14.6 million.
The gap between the two numbers is C$47.9 million in non-cash revaluation gains. Strip those out and the picture is of a company whose operating engine is still being built, even as it courts a second stock exchange listing in Korea and reshuffles its board.
Revenue for the quarter reached C$41.9 million, up 382% year over year — the strongest operational signal in the report. Sangdong, the company's flagship mine, produced tungsten concentrate for the first time in September, and more than 90% of Phase I output is already locked into contracts.
Analysts Trim Targets as Sangdong Deliveries Slip
The market's reaction has been less enthusiastic than the revenue line might suggest. B. Riley Securities cut its price target on Monday to US$18 from US$20 while keeping a Buy rating, citing delayed shipments from Sangdong and expecting only a minimal contribution from the mine in the fourth quarter of 2026. Stifel had already reduced its own target to US$18 from US$21 on Friday, also maintaining a Buy call.
The shares fell 2.4% on Wednesday evening and are down 9.4% over 30 days.
Should investors sell immediately? Or is it worth buying Almonty?
Liquidity is not the issue. Almonty reported cash of C$1.15 billion as of September 30, a cushion that gives it room to absorb setbacks — though it substitutes neither for recurring earnings nor for a resolution of disputed claims.
A US$67 Million Claim and a Counterclaim
Those claims are substantial. Deutsche Rohstoff, an Almonty shareholder, said in its quarterly report that it is pursuing roughly US$67 million against the company, tied mainly to conversion rights and outstanding loans. Almonty has filed its own suit, and the two cases have been consolidated. Deutsche Rohstoff has called the allegations against it unfounded and largely time-barred; it said separately on Wednesday that Almonty's action centers chiefly on claims connected to the 2014 sale of Wolfram Camp.
None of this amounts to a court-established liability, and Almonty's counterclaim is no guarantee of a favorable outcome either. What investors must weigh is which claims will actually stick and what the financial consequences would be.
The bear case sharpens if operating momentum fades at the same time as a legal setback lands. Under those conditions, revaluation gains would not offset the economic hit — and a large reported net profit would be no defense. The two risks deserve separate scrutiny rather than being netted against the revenue trajectory.
Korea Listing and a Board in Transition
Almonty said Wednesday it is pursuing a secondary listing on the Korea Exchange, subject to exchange and regulatory approvals, market conditions, and compliance with securities requirements. If completed, it would widen access to the stock — a complement to a strengthening operating base, not a replacement for one.
On the governance front, David Hanick and Andrew Frazer are set to leave the board on December 31, 2026, though both will remain with the company in other roles. Eugene Bae and Jim Rudyk were appointed independent directors effective immediately on Wednesday.
For all the corporate activity, the investment question comes down to whether Almonty can convert its revenue surge into durable operating profit. Adjusted EBITDA of C$14.6 million is a start. Whether it becomes a trend is what the next set of numbers will have to prove.
Ad
Almonty Stock: New Analysis - 18 November
Fresh Almonty information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
